Confirmed Exhibitors
SSO ASM 2025 exhibitors
We’re proud to welcome our confirmed exhibitors for SSO ASM 2025 and extend our sincere thanks for their support and partnership.
These organisations play a vital role in advancing oncology through innovation, technology, and collaboration. Attendees can look forward to engaging with leading names in the field and discovering the latest developments that support cancer care and research.
Exhibitors
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.
(https://beonemedicines.com/)
Driven by our mission to provide better healthcare for all, we bring life-saving and life-changing drugs, medicines, supplements, vaccines, treatments, and medical devices to patients – bridging the inequality gap and improving patient outcomes by supporting our partners with a full range of commercial outsourcing and market expansion services.
(https://www.dksh.com/sg-en/home)
Johnson & Johnson Innovative Medicine is leading where medicine is going. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow.
(https://innovativemedicine.jnj.com/apac/)
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
(www.takeda.com)
Contact Us
For more information regarding all opportunities available, please contact us at ssoasm-partnerships@icsevents.com